Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Revance The (RVNC) stocks

Learn how to easily invest in Revance The stocks.

Revance The is a biotechnology business based in the US. Revance The stocks (RVNC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $32.77 – an increase of 1.97% over the previous week. Revance The employs 534 staff and has a trailing 12-month revenue of around $156.6 million.

How to buy Revance The stock

  1. Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – RVNC. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Promoted for Beginners

National Bank Direct Brokerage


  • Commission-free trading
  • Several account types available
  • Access to array of research tools

Promoted for Low Fees

CIBC Investor's Edge


  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers


  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Revance The stock price (NASDAQ:RVNC)

Use our graph to track the performance of RVNC stocks over time.

Revance The shares at a glance

Information last updated 2023-06-04.
Latest market close$31.06
52-week range$11.27 - $37.98
50-day moving average $32.32
200-day moving average $27.62
Wall St. target price$39.42
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.82

Buy Revance The stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
CIBC Investor's Edge
Finder Rating:
★★★★★
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95–$6.95
$0 if conditions met, or $100
N/A
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Interactive Brokers
Finder Rating:
★★★★★
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
$0
N/A
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
National Bank Direct Brokerage
Finder Rating:
★★★★★
4.2 / 5
Stocks, Bonds, Options, Mutual Funds, GICs
$0
$0 if conditions met, or $100
Get $0 commission on all transactions with promo code: finder
Questrade
Finder Rating:
★★★★★
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
$0
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
Qtrade Direct Investing
Finder Rating:
★★★★★
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 sign-up bonus. Use promo code BONUS150. Conditions apply. Ends June 30, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.
loading

Is it a good time to buy Revance The stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Revance The price performance over time

Historical closes compared with the close of $31.06 from 2023-06-02

1 week (2023-05-26) 1.97%
1 month (2023-05-04) -8.05%
3 months (2023-03-03) -6.19%
6 months (2022-12-02) 40.23%
1 year (2022-06-02) 133.71%
2 years (2021-06-04) 11.13%
3 years (2020-06-04) 45.48%
5 years (2018-06-04) 7.85%
[/expander_content] [/expander]

Revance The financials

Revenue TTM $156.6 million
Gross profit TTM $-20,388,000
Return on assets TTM -28.21%
Return on equity TTM -879.28%
Profit margin -224.65%
Book value $-0.32
Market capitalisation $2.6 billion

TTM: trailing 12 months

Revance The share dividends

We're not expecting Revance The to pay a dividend over the next 12 months.

Revance The share price volatility

Over the last 12 months, Revance The's shares have ranged in value from as little as $11.27 up to $37.98. A popular way to gauge a stock's volatility is its "beta".

RVNC.US volatility(beta: 0.84)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Revance The's is 0.8392. This would suggest that Revance The's shares are less volatile than average (for this exchange).

Revance The overview

Revance Therapeutics, Inc. , a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site